Abstract
To the Editor: Dupilumab is a fully human monoclonal antibody that binds the interleukin (IL) 4 receptor-α subunit and inhibits signaling of IL-4 and IL-13. It was approved by the Food and Drug Administration for the treatment of moderate to severe atopic dermatitis in adults and adolescents, with efficacy in reducing pruritus.1 The 2 most common subtypes of cutaneous T-cell lymphoma are mycosis fungoides and Sézary syndrome. Mycosis fungoides, Sézary syndrome and atopic dermatitis are similarly driven by T-helper 2 cytokine profiles2 and may present with similar morphology (ie, erythema, lichenification, fissuring) with pruritus,3 disruption of the skin barrier, and impetiginization.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
